卵巢癌是最致命的妇科恶性肿瘤，占所有妇科癌症相关死亡人数的近 65%。早期检测和诊断的挑战，加上癌细胞腹膜内广泛扩散和对化疗的耐药性，极大地导致了这种疾病的高死亡率。由于缺乏特异性症状且缺乏有效的筛查方法，大多数卵巢癌病例确诊时已处于晚期。虽然化疗是一种常见的治疗方法，但它常常导致肿瘤复发，需要进一步的干预。近年来，抗体药物偶联物（ADC）已成为靶向癌症治疗的重要工具。这些复杂的生物治疗药物通过连接体将特异性靶向肿瘤特异性/相关抗原的抗体与高效抗癌药物结合起来，为卵巢癌治疗提供了一种有前景的方法。各种人类肿瘤中分子靶标的识别为靶向治疗的开发铺平了道路，而 ADC 处于这一创新的最前沿。通过将细胞毒性药物直接递送至肿瘤和转移性病灶，ADC 在治疗化疗耐药性卵巢癌方面显示出潜力。与正常和/或良性样本相比，MUC16、MUC13 和 MUC1 等粘蛋白在卵巢肿瘤中表现出显着更高的表达，因此已成为 ADC 生成的有希望的靶标。虽然传统标志物因其在非癌症条件下水平升高而受到限制，但粘蛋白为卵巢癌的靶向治疗提供了新的可能性。这篇综述全面描述了粘蛋白在 ADC 疗法中的潜力，强调了它们在改善卵巢癌患者预后方面的重要性。© 2024。作者。

Ovarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65% of all gynecologic cancer-related deaths. The challenges in early detection and diagnosis, coupled with the widespread intraperitoneal spread of cancer cells and resistance to chemotherapy, contribute significantly to the high mortality rate of this disease. Due to the absence of specific symptoms and the lack of effective screening methods, most ovarian cancer cases are diagnosed at advanced stages. While chemotherapy is a common treatment, it often leads to tumor recurrence, necessitating further interventions. In recent years, antibody-drug conjugates (ADCs) have emerged as a valuable tool in targeted cancer therapy. These complex biotherapeutics combine an antibody that specifically targets tumor specific/associated antigen(s) with a high potency anti-cancer drug through a linker, offering a promising approach for ovarian cancer treatment. The identification of molecular targets in various human tumors has paved the way for the development of targeted therapies, with ADCs being at the forefront of this innovation. By delivering cytotoxic agents directly to tumors and metastatic lesions, ADCs show potential in managing chemo-resistant ovarian cancers. Mucins such as MUC16, MUC13, and MUC1 have shown significantly higher expression in ovarian tumors as compared to normal and/or benign samples, thus have become promising targets for ADC generation. While traditional markers are limited by their elevated levels in non-cancerous conditions, mucins offer a new possibility for targeted treatment in ovarian cancer. This review comprehensively described the potential of mucins for the generation of ADC therapy, highlighting their importance in the quest to improve the outcome of ovarian cancer patients.© 2024. The Author(s).